| Literature DB >> 34481459 |
Yemei Liu1, Pei Yang1, Yong Pi2, Lisha Jiang1, Xiao Zhong1, Junjun Cheng1, Yongzhao Xiang1, Jianan Wei2, Lin Li1, Zhang Yi2, Huawei Cai3, Zhen Zhao4.
Abstract
BACKGROUND: We aimed to construct an artificial intelligence (AI) guided identification of suspicious bone metastatic lesions from the whole-body bone scintigraphy (WBS) images by convolutional neural networks (CNNs).Entities:
Keywords: Artificial intelligence; Bone metastasis; Bone scintigraphy; Convolutional neural network
Mesh:
Year: 2021 PMID: 34481459 PMCID: PMC8417997 DOI: 10.1186/s12880-021-00662-9
Source DB: PubMed Journal: BMC Med Imaging ISSN: 1471-2342 Impact factor: 1.930
Fig. 1The diagram of manual annotation in WBS image. All visible bone lesions were delineated and annotated as benign and malignant. Red areas represent malignant lesions, while green areas represent benign lesions
Fig. 2Architecture of convolutional neural network for AI model
The summary of patient-based and lesion-based analysis in all WBS images
| Lung cancer | Prostate cancer | Breast cancer | Total | |
|---|---|---|---|---|
| Total | 1253 | 1017 | 1082 | 3352 |
| Malignant | 567 | 466 | 437 | 1470 |
| Benign | 686 | 551 | 645 | 1882 |
| Metastasis rate | 45.25% | 45.82% | 40.39% | 43.85% |
| Total | 4937 | 5623 | 4412 | 14,972 |
| Malignant | 2475 | 3227 | 1968 | 7670 |
| Benign | 2462 | 2396 | 2444 | 6812 |
| Metastasis rate | 50.13% | 57.39% | 44.61% | 51.23% |
The fivefold cross validation results of the proposed network
| Fold 1 | Fold 2 | Fold 3 | Fold 4 | Fold 5 | |
|---|---|---|---|---|---|
| Number of patients (benign/malignant) | 669 (376/293) | 669 (376/293) | 671 (376/295) | 669 (376/293) | 674 (378/296) |
| Number of lesions (benign/malignant) | 2986 (1505/1481) | 2952 (1389/1563) | 3084 (1468/1616) | 2897 (1475/1422) | 3053 (1465/1588) |
| Sensitivity | 83.19 | 83.11 | 79.89 | 76.79 | 83.5 |
| Specificity | 78.07 | 82.58 | 82.7 | 82.78 | 79.59 |
| Accuracy | 80.61 | 82.86 | 81.23 | 79.84 | 81.62 |
| PPV | 78.87 | 84.3 | 83.56 | 81.13 | 81.6 |
| NPV | 82.51 | 81.29 | 78.88 | 78.72 | 81.65 |
The comparison of the proposed network and other three networks
| Sensitivity | Specificity | Accuracy | PPV | NPV | |
|---|---|---|---|---|---|
| Our model | 81.30 | 81.14 | 81.23 | 81.89 | 80.61 |
| InceptionV3 | 77.29 | 84.02 | 80.61 | 83.53 | 78.00 |
| VGG16 | 78.73 | 83.51 | 81.13 | 83.39 | 79.14 |
| DenseNet169 | 67.90 | 85.73 | 76.71 | 83.17 | 72.16 |
The lesion-based diagnostic performance of AI model in testing cohort and the comparison of the AI performance among few, medium and extensive lesion groups
| Group for number of lesions | χ2 | ||||
|---|---|---|---|---|---|
| Few | Medium | Extensive | |||
| Sensitivity | 58.63 | 64.34 | 89.56 | 163.41 | < 0.001 |
| Specificity | 89.41 | 85.24 | 62.85 | 108.69 | < 0.001 |
| Accuracy | 81.78 | 78.03 | 82.79 | 8.06 | 0.018 |
| PPV | 64.89 | 69.67 | 87.37 | 83.70 | < 0.001 |
| NPV | 86.76 | 82.04 | 67.93 | 49.24 | < 0.001 |
Chi-square test was performed to compare the performance of AI model among different groups of the number of lesions. Few lesions group: 1–3 lesions per image; Medium lesions group: 4–6 lesions per image; Extensive lesions group: > 6 lesions per image
Fig. 3The confusion matrix of few lesions group (A), medium lesions group (B), extensive lesions group (C). The ROC of the three groups in the lesion-based diagnosis (D)
The lesion-based diagnostic performance of AI model in the testing cohort and the comparison of the AI performance among lung, prostate and breast cancers
| Group for primary tumor types | χ2 | ||||
|---|---|---|---|---|---|
| Lung cancer | Prostate cancer | Breast cancer | |||
| Sensitivity | 76.16 | 84.66 | 81.65 | 12.88 | 0.002 |
| Specificity | 82.52 | 79.07 | 81.78 | 2.08 | 0.354 |
| Accuracy | 79.40 | 82.30 | 81.82 | 3.13 | 0.209 |
| PPV | 81.12 | 84.43 | 78.33 | 6.52 | 0.038 |
| NPV | 77.70 | 79.52 | 85.05 | 8.85 | 0.012 |
Chi-square test was performed to compare the performance of AI model among different tumor types
Fig. 4The confusion matrix of lung cancer group (A), prostate cancer group (B), breast cancer group (C). The ROC of the three groups in the lesion-based diagnosis (D)